KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) EBITDA (2016 - 2025)

Historic EBITDA for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to -$160.2 million.

  • Ionis Pharmaceuticals' EBITDA fell 775.35% to -$160.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$278.0 million, marking a year-over-year increase of 2492.97%. This contributed to the annual value of -$475.1 million for FY2024, which is 3430.61% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported EBITDA of -$160.2 million as of Q3 2025, which was down 775.35% from $139.8 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year EBITDA high stood at $220.6 million for Q4 2021, and its period low was -$208.0 million during Q4 2022.
  • Over the past 5 years, Ionis Pharmaceuticals' median EBITDA value was -$90.2 million (recorded in 2023), while the average stood at -$75.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 107336.3% in 2021, then plummeted by 171020.91% in 2024.
  • Ionis Pharmaceuticals' EBITDA (Quarter) stood at $220.6 million in 2021, then crashed by 194.3% to -$208.0 million in 2022, then skyrocketed by 97.06% to -$6.1 million in 2023, then plummeted by 1710.21% to -$110.8 million in 2024, then plummeted by 44.54% to -$160.2 million in 2025.
  • Its last three reported values are -$160.2 million in Q3 2025, $139.8 million for Q2 2025, and -$146.9 million during Q1 2025.